Look deeper.
Decide with context.
A practical view across the peptide landscape. Follow the evidence, compare mechanisms, and see where established medicine gives way to ongoing research.
Browse every profileThe landscape at a glance.
Evidence has layers.
These counts describe the library, not a ranking of treatments. Approval applies to specific products and indications. Early research can identify a question without answering it.
How to read this viewCounts reflect 48 profiles in this reference library. They do not measure safety, effectiveness, or availability.
Where the research sits.
Each cell counts profiles in a research area and evidence stage. Choose a cell to explore the corresponding profiles.
Scroll across the table to explore every evidence stage.
Put them side by side.
Compare up to three profiles. See what differs before the conversation turns to availability.
A clearer view starts with a comparison.
Choose a peptide above, or select profiles in the library.
A second look
at the wording.
We use JEV to check whether evidence context and availability language are clear. This automated review assesses the profile text. It does not verify sources or measure medical safety, effectiveness, or suitability.
Read the methodologyReviewed November 5, 2026. A clarity score below 0.75 flags a profile for review.
See the review records
Model: typesafe/jev-1.13-20260917. Each value is a model assessment on a 0 to 1 scale. It is not a clinical confidence score or a probability of benefit.
| Profile | Evidence context clarity | Availability wording clarity | Flagged |
|---|---|---|---|
| Abaloparatide | 0.97 | 0.97 | No |
| Acetyl hexapeptide-8 | 0.95 | 0.97 | No |
| Afamelanotide | 0.96 | 0.97 | No |
| AOD-9604 | 0.90 | 0.96 | No |
| BPC-157 | 0.96 | 0.97 | No |
| Bremelanotide | 0.97 | 0.97 | No |
| Cagrilintide | 0.92 | 0.97 | No |
| CJC-1295 | 0.96 | 0.97 | No |
| Davunetide | 0.95 | 0.97 | No |
| DSIP | 0.92 | 0.97 | No |
| Elamipretide | 0.95 | 0.97 | No |
| Epitalon | 0.96 | 0.97 | No |
| Exenatide | 0.95 | 0.97 | No |
| GHK-Cu | 0.96 | 0.97 | No |
| GHRP-2 | 0.93 | 0.97 | No |
| GHRP-6 | 0.88 | 0.97 | No |
| Glutathione | 0.92 | 0.97 | No |
| Gonadorelin | 0.94 | 0.97 | No |
| Hexarelin | 0.91 | 0.97 | No |
| Humanin | 0.96 | 0.97 | No |
| IDR-1018 | 0.94 | 0.97 | No |
| Ipamorelin | 0.96 | 0.97 | No |
| Kisspeptin-10 | 0.93 | 0.97 | No |
| KPV | 0.97 | 0.97 | No |
| Leuprolide | 0.96 | 0.97 | No |
| Liraglutide | 0.96 | 0.97 | No |
| LL-37 | 0.96 | 0.97 | No |
| Mazdutide | 0.94 | 0.96 | No |
| MOTS-c | 0.96 | 0.97 | No |
| Nerinetide | 0.95 | 0.97 | No |
| Palmitoyl pentapeptide-4 | 0.95 | 0.97 | No |
| Pramlintide | 0.96 | 0.97 | No |
| RDP58 | 0.94 | 0.97 | No |
| Retatrutide | 0.91 | 0.97 | No |
| Selank | 0.93 | 0.97 | No |
| Semaglutide | 0.96 | 0.97 | No |
| Semax | 0.94 | 0.97 | No |
| Sermorelin | 0.95 | 0.96 | No |
| SHLP2 | 0.95 | 0.97 | No |
| Survodutide | 0.94 | 0.96 | No |
| TB-500 | 0.92 | 0.97 | No |
| Teriparatide | 0.97 | 0.97 | No |
| Tesamorelin | 0.97 | 0.97 | No |
| Thymopentin | 0.95 | 0.97 | No |
| Thymosin alpha-1 | 0.95 | 0.97 | No |
| Thymosin beta-4 | 0.96 | 0.97 | No |
| Tirzepatide | 0.96 | 0.97 | No |
| Ziconotide | 0.97 | 0.97 | No |
Context matters
as much as the count.
What these numbers mean
The totals are calculated from this library. A category is a way to explore a biological target or research area, not a treatment recommendation. One primary reference is linked from each profile.
What approval does and does not mean
An approved medicine is a specific product for specific indications. That precedent does not make every preparation, compound, use, or pharmacy offering approved. Check the source and the relevant pharmacy pathway.
Why early research is different
Cell and animal studies, early human studies, and approved-product evidence answer different questions. They should not be combined into a single effectiveness score. Study quality, population, formulation, and outcomes all matter.
What requires a professional review
Clinical appropriateness, prescribing, compounding eligibility, and dispensing remain with licensed professionals. The library is educational and is not a formulary or a promise of supply.
Bring better questions.
Start a partner conversation with your business model, clinical pathway, and operational needs in view.